421 related articles for article (PubMed ID: 32450839)
1. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.
Reis LMD; Adamoski D; Ornitz Oliveira Souza R; Rodrigues Ascenção CF; Sousa de Oliveira KR; Corrêa-da-Silva F; Malta de Sá Patroni F; Meira Dias M; Consonni SR; Mendes de Moraes-Vieira PM; Silber AM; Dias SMG
J Biol Chem; 2019 Jun; 294(24):9342-9357. PubMed ID: 31040181
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
[TBL] [Abstract][Full Text] [Related]
5. Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer.
Zhou R; Bagga P; Nath K; Hariharan H; Mankoff DA; Reddy R
Cancer Res; 2018 Oct; 78(19):5521-5526. PubMed ID: 30072394
[TBL] [Abstract][Full Text] [Related]
6. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
7. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
8. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
[TBL] [Abstract][Full Text] [Related]
9. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of eEF2K synergizes with glutaminase inhibitors or 4EBP1 depletion to suppress growth of triple-negative breast cancer cells.
Ju Y; Ben-David Y; Rotin D; Zacksenhaus E
Sci Rep; 2021 Apr; 11(1):9181. PubMed ID: 33911160
[TBL] [Abstract][Full Text] [Related]
11. [
Zhou R; Pantel AR; Li S; Lieberman BP; Ploessl K; Choi H; Blankemeyer E; Lee H; Kung HF; Mach RH; Mankoff DA
Cancer Res; 2017 Mar; 77(6):1476-1484. PubMed ID: 28202527
[TBL] [Abstract][Full Text] [Related]
12. Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells.
Chen L; Cui H; Fang J; Deng H; Kuang P; Guo H; Wang X; Zhao L
Oncotarget; 2016 Aug; 7(34):54691-54701. PubMed ID: 27419628
[TBL] [Abstract][Full Text] [Related]
13. GLS2 is protumorigenic in breast cancers.
Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
[TBL] [Abstract][Full Text] [Related]
14. A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.
Chen Y; Zhao Y; Bajor DL; Wang Z; Selfridge JE
J Genet Genomics; 2020 Jul; 47(7):389-395. PubMed ID: 33004309
[TBL] [Abstract][Full Text] [Related]
15. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells.
Cheng T; Sudderth J; Yang C; Mullen AR; Jin ES; Matés JM; DeBerardinis RJ
Proc Natl Acad Sci U S A; 2011 May; 108(21):8674-9. PubMed ID: 21555572
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
[TBL] [Abstract][Full Text] [Related]
17. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition.
Muir A; Danai LV; Gui DY; Waingarten CY; Lewis CA; Vander Heiden MG
Elife; 2017 Aug; 6():. PubMed ID: 28826492
[TBL] [Abstract][Full Text] [Related]
18. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells.
Steifensand F; Gallwas J; Bauerschmitz G; Gründker C
Cells; 2021 Sep; 10(9):. PubMed ID: 34572047
[TBL] [Abstract][Full Text] [Related]
20. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
